+

WO1999050289A3 - Genes associes a l'evolution des tumeurs et methodes d'utilisation - Google Patents

Genes associes a l'evolution des tumeurs et methodes d'utilisation Download PDF

Info

Publication number
WO1999050289A3
WO1999050289A3 PCT/US1999/007187 US9907187W WO9950289A3 WO 1999050289 A3 WO1999050289 A3 WO 1999050289A3 US 9907187 W US9907187 W US 9907187W WO 9950289 A3 WO9950289 A3 WO 9950289A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
progression
related genes
cancer
monitoring
Prior art date
Application number
PCT/US1999/007187
Other languages
English (en)
Other versions
WO1999050289A2 (fr
Inventor
Nan Zhang
Paul B Fisher
Original Assignee
Nan Zhang
Paul B Fisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nan Zhang, Paul B Fisher filed Critical Nan Zhang
Priority to AU34627/99A priority Critical patent/AU3462799A/en
Publication of WO1999050289A2 publication Critical patent/WO1999050289A2/fr
Publication of WO1999050289A3 publication Critical patent/WO1999050289A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des méthodes destinées au diagnostic, au suivi et au traitement du cancer. Les composés de l'invention sont des protéines associées à l'évolution des tumeurs, des parties et des variantes desdites protéines, ainsi que des polynucléotides codant pour ces polypeptides, des anticorps fixant ces polypeptides et des agents modulant l'expression de ces polypeptides. L'invention concerne également des vaccins et des compositions pharmaceutiques renfermant de tels composés, lesquels vaccins et compositions peuvent être utilisés, par exemple, pour la prévention et le traitement du cancer. Les polypeptides peuvent également être utilisés comme marqueurs permettant de suivre la progression du cancer chez un patient.
PCT/US1999/007187 1998-03-31 1999-03-31 Genes associes a l'evolution des tumeurs et methodes d'utilisation WO1999050289A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34627/99A AU3462799A (en) 1998-03-31 1999-03-31 Progression related genes and methods of use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8019398P 1998-03-31 1998-03-31
US60/080,193 1998-03-31

Publications (2)

Publication Number Publication Date
WO1999050289A2 WO1999050289A2 (fr) 1999-10-07
WO1999050289A3 true WO1999050289A3 (fr) 2000-01-20

Family

ID=22155843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007187 WO1999050289A2 (fr) 1998-03-31 1999-03-31 Genes associes a l'evolution des tumeurs et methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU3462799A (fr)
WO (1) WO1999050289A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284362A2 (fr) * 1987-03-23 1988-09-28 Imperial Chemical Industries Plc Marqueurs moléculaires
WO1990002203A1 (fr) * 1988-08-19 1990-03-08 Scanlon Kevin J Detection de la progression et de la resistance aux medicaments de tumeurs chez l'homme
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1998042315A1 (fr) * 1997-03-21 1998-10-01 The Trustees Of Columbia University In The City Of New York Identification du gene eleve de progression 3 et utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284362A2 (fr) * 1987-03-23 1988-09-28 Imperial Chemical Industries Plc Marqueurs moléculaires
WO1990002203A1 (fr) * 1988-08-19 1990-03-08 Scanlon Kevin J Detection de la progression et de la resistance aux medicaments de tumeurs chez l'homme
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1998042315A1 (fr) * 1997-03-21 1998-10-01 The Trustees Of Columbia University In The City Of New York Identification du gene eleve de progression 3 et utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONALDO MF ET AL.: "U1-R-E1 Rat c-DNA clone; EST", EMBL SEQUENCE DATABASE, 8 May 1998 (1998-05-08), HEIDELBERG DE, XP002112265 *
SU Z-Z ET AL: "Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 94, no. 17, August 1997 (1997-08-01), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 9125 - 9130, XP002112264, ISSN: 0027-8424 *
SYKES D.E. ET AL.: "Rattus norvegicus clone C426 intestinal epithelium proliferating cell-associated mRNA sequences", EMBL SEQUENCE DATABASE, 13 April 1995 (1995-04-13), HEIDELBERG DE, XP002112263 *

Also Published As

Publication number Publication date
WO1999050289A2 (fr) 1999-10-07
AU3462799A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
WO1999033869A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
WO1997025426A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein
WO2000061612A3 (fr) Composes et procedes de therapie et de diagnostic du cancer du poumon
WO1999038973A3 (fr) Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO1999047674A3 (fr) Composes et methodes therapeutiques et diagnostiques du cancer du poumon
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
WO2001092581A3 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l'ovaire
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation
WO2002004514A8 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2000060076A3 (fr) Compositions pour le traitement et le diagnostic du cancer du sein et leurs procedes d'utilisation
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2002074237A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO1998045328A3 (fr) Compositions therapeutiques et diagnostiques du carcinome mammaire et methodes afferentes
WO2002058534A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2000061756A3 (fr) Composes pour l'immunotherapie et le diagnostic du cancer du sein et procedes d'utilisation
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
WO2000013712A3 (fr) Methodes et compositions pour la prevention ou le traitement du cancer
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2002000174A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du poumon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载